Eli Lilly has revealed that the highest dose of Lepodisiran has significantly reduced risk factors for inherited heart disease in mid-stage clinical trials.
When participants took 400 mg of Lepodisiran, either once or twice, their lipoprotein levels dropped by an impressive 93.9% compared to the placebo over 6 months. Notably, no serious side effects related to the drug were reported during the trial.
Lepodisiran is one of several medications currently being tested to treat elevated lipoprotein, a major risk factor for heart disease that affects approximately 1.4 billion people globally, including 64 million Americans.
While LDL, often called bad cholesterol, can be controlled through diet and statin medications, there are currently no FDA-approved treatments for high lipoprotein levels. Elevated lipoprotein levels increase the risk of severe conditions like heart attacks, strokes, aortic valve disease, and peripheral artery disease—health issues that affect millions of Americans each year.
Eli Lilly has already moved Lepodisiran into late-stage clinical trials, marking a critical step forward in developing potential treatments for this heart disease risk factor.
